Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

769
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
769
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

784
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
784
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

713
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
713
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

827
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
827
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.4K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.4K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

336
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
336

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunological consequences of senescence in physiology and pathology.

Journal of translational medicine·2026
Same author

Acyl-CoA-binding protein (ACBP): a poor-prognosis biomarker in sepsis and a target for disease mitigation.

Signal transduction and targeted therapy·2026
Same author

Acyl-CoA-binding protein as a driver of pathological aging.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Corrigendum to "Early vascular aging in chronic kidney disease: focus on microvascular maintenance, senescence signature and potential therapeutics" [Translational Research 275 (2025) 32-47].

Translational research : the journal of laboratory and clinical medicine·2024
Same author

ACBP/DBI neutralization for the experimental treatment of fatty liver disease.

Cell death and differentiation·2024
Same author

Early vascular aging in chronic kidney disease: focus on microvascular maintenance, senescence signature and potential therapeutics.

Translational research : the journal of laboratory and clinical medicine·2024

Related Experiment Video

Updated: Mar 8, 2026

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

1.2K

Metformin: a metabolic modulator.

Federico Pietrocola1,2,3,4,5,6, Guido Kroemer1,2,3,4,5,6,7,8

  • 1Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.

Oncotarget
|January 26, 2017
PubMed
Summary
This summary is machine-generated.

Metformin, a biguanide drug, reduces cellular energy by inhibiting mitochondria. This impacts nuclear pore complex function, blocks mTOR signaling, and boosts ACAD10 expression, potentially explaining its anti-aging and anti-cancer effects.

Keywords:
agingautophagybiguanidescaloric restrictioncancer

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K
Fixation and Operational Method for Abdominal Massage in T2DM Mice
05:57

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

839

Related Experiment Videos

Last Updated: Mar 8, 2026

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

1.2K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K
Fixation and Operational Method for Abdominal Massage in T2DM Mice
05:57

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

839

Area of Science:

  • Biochemistry
  • Cell Biology
  • Aging Research

Background:

  • Biguanides, like metformin, are known for their anti-diabetic properties.
  • Emerging evidence suggests biguanides possess anti-aging and cytostatic effects.
  • The precise molecular mechanisms underlying these effects require further elucidation.

Purpose of the Study:

  • To investigate the molecular mechanisms of biguanide action in aging and cancer.
  • To explore the role of mitochondrial activity and downstream signaling pathways.
  • To examine the impact on nuclear pore complex function and gene expression.

Main Methods:

  • Studies were conducted in Caenorhabditis elegans and human cell lines.
  • Metformin was used to inhibit mitochondrial activity.
  • Analysis included assessment of energy charge, mTOR signaling, nuclear pore complex function, and ACAD10 expression.

Main Results:

  • Metformin-induced inhibition of mitochondrial activity led to a drop in cellular energy charge.
  • This energy drop affected nuclear pore complex function and inhibited mTOR signaling.
  • Enhanced expression of ACAD10 was observed following metformin treatment.

Conclusions:

  • Metformin's effects on cellular energy, nuclear pore complex, and mTOR signaling are key to its observed anti-aging and cytostatic properties.
  • ACAD10 upregulation is a downstream consequence of metformin's mitochondrial inhibition.
  • Further research is needed to confirm if these mechanisms fully explain metformin's therapeutic benefits in mammals for diabetes and cancer.